"Caribou Biosciences Announces Closing of Upsized IPO"
"Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the underwriting discoun
"Learning to Love G.M.O.s"
"On a cold December day in Norwich, England, Cathie Martin met me at a laboratory inside the John Innes Centre, where she works. A plant biologist, Martin has spent almost two decades studying tomatoes, and I had traveled to see her because of a particular one she created: a lustrous, dark purple variety that is unusually high in antioxidants, with twice the amount found in blueberries. At 66, Martin has silver-white hair, a strong chin and sharp eyes that give her a slightly
